PCI Biotech Holding ASA
OSE:PCIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AURELIUS Equity Opportunities SE & Co KgaA
XETRA:AR4
|
DE |
|
U
|
Ucap Cloud Information Technology Co Ltd
SSE:688228
|
CN |
|
W
|
Weibo Corp
HKEX:9898
|
CN |
|
J
|
Jangho Group Co Ltd
SSE:601886
|
CN |
|
FS Development Investment Holdings
SZSE:300071
|
CN |
PCI Biotech Holding ASA
EPS (Diluted)
PCI Biotech Holding ASA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PCI Biotech Holding ASA
OSE:PCIB
|
EPS (Diluted)
kr0
|
CAGR 3-Years
37%
|
CAGR 5-Years
20%
|
CAGR 10-Years
10%
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
EPS (Diluted)
kr0
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
EPS (Diluted)
$0
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
EPS (Diluted)
kr0
|
CAGR 3-Years
82%
|
CAGR 5-Years
69%
|
CAGR 10-Years
49%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
EPS (Diluted)
kr0
|
CAGR 3-Years
67%
|
CAGR 5-Years
53%
|
CAGR 10-Years
26%
|
|
PCI Biotech Holding ASA
Glance View
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2008-06-18. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. The company focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.
See Also
What is PCI Biotech Holding ASA's EPS (Diluted)?
EPS (Diluted)
-0.6
NOK
Based on the financial report for Jun 30, 2025, PCI Biotech Holding ASA's EPS (Diluted) amounts to -0.6 NOK.
What is PCI Biotech Holding ASA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
10%
Over the last year, the EPS (Diluted) growth was 26%. The average annual EPS (Diluted) growth rates for PCI Biotech Holding ASA have been 37% over the past three years , 20% over the past five years , and 10% over the past ten years .
